Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
OBT to receive up to US$36 million upfront payments and may be eligible to receive milestone payments potentially exceeding US$1 billion, as well as royalties
Oxford, UK and San Jose, California, 19th March 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year collaboration with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.
OBT's recently launched enhanced proprietary OGAP®-Verify discovery platform enables greater sensitivity and thereby the selection of targets with improved attributes for drug development.
Under the terms of the agreement, targets are identified via the OGAP®-Verify discovery platform and will be validated through the research collaboration. Any further research, development and commercialization efforts against these targets will be driven by Roche. OBT will receive up to US$36 million upfront payments from Roche and may be eligible to receive milestone payments potentially exceeding US$1 billion, plus product royalties on net sales.
'We are proud to partner with Roche, a global leader in oncology, to accelerate the application of novel cancer targets identified through our proprietary discovery platform, OGAP-Verify,' said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics. 'This collaboration builds on our efforts to enhance, validate and advance the discovery of oncology targets, and we look forward to leveraging Roche's deep expertise to translate these insights into potential new treatments for patients. Our discovery philosophy is very patient centric and Roche's strength to integrate pharma and diagnostics is unique in the industry.'
'We are excited to enter into this strategic collaboration with OBT. By combining Roche's expertise in discovering and developing transformative therapeutics with OBT's innovative target discovery platform, we aim to unlock new possibilities in cancer treatment', said Boris L. Zaïtra, Head of Corporate Business Development at Roche. 'This partnership underscores our commitment to advancing potentially first-in-class antibody-based therapeutics. Together, we aim to accelerate the development of innovative therapies that address major unmet patient needs in oncology.'
About Oxford BioTherapeutics
Oxford BioTherapeutics is a clinical stage oncology company discovering and developing first in class antibody-based therapies designed to fulfil major unmet patient needs in cancer therapy. These include Bispecific Antibodies and Antibody Drug Conjugate (ADC) therapeutics.
OBT is dedicated to discovering and validating the next generation of ADC targets for safe and effective medicines. The OGAP-Verify platform's enhanced sensitivity, specificity, and reliability will significantly accelerate biopharma's capabilities to identify and validate human targets with robust scientific support. Our commitment to leveraging OGAP capabilities underscores our dedication to advancing the forefront of cancer therapy development, with three programs originating from this technology now in clinical development in the US and Europe. OBTs IO discovery process provides unique insights into the cancer-immune cell synapse and has identified several novel IO monoclonal and bispecific antibody candidates for cancer therapies.
OBT's lead clinical program, OBT076, initiated expansion in a US Clinical Trial in 2021 in patients with advanced or refractory solid tumors, including gastric, bladder, ovarian and lung cancer, where CD205 is overexpressed. Infiltration of tumors by immunosuppressive cells correlates with adverse outcomes (lower progression free and overall survival), suggesting that this process contributes to the progression of several cancers.
OBT's pipeline and development capabilities have been validated through multiple strategic partnerships including with Boehringer Ingelheim, ImmunoGen (now part of Abbvie) and Zymeworks as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS) and Alere (Abbott). OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.
For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com and follow us on LinkedIn.
Partnering:Dr Christian Rohlff, CEOPartnering@oxfordbiotherapeutics.com
Media:MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Erica HollingsworthE : OBT@medistrava.comT : +44 (0)203 928 6900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Trump Administration Posts Guidance on Tariff Rollout
(Bloomberg) -- President Donald Trump's expanded reciprocal tariffs will not apply to any products loaded onto a vessel for transport into the US before 12:01 a.m. New York time on Thursday, according to guidance issued by US Customs and Border Protection. PATH Train Service Resumes After Fire at Jersey City Station Chicago Curbs Hiring, Travel to Tackle $1 Billion Budget Hole Seeking Relief From Heat and Smog, Cities Follow the Wind Mayor Asked to Explain $1.4 Billion of Wasted Johannesburg Funds The notice, posted by the federal government on Monday, outlines implementation of the tariffs Trump announced last week, which are expected to ratchet up levies on dozens of trading partners. Expected exemptions for products under the US-Mexico-Canada free trade agreement negotiated by the president during his first term are included in the document, as are exemptions for relief items like food, clothing and medicine set to be distributed as aid. So is the president's threatened penalty of a 40% tariff on goods deemed by the federal government to be transshipped to avoid country-specific duties. Taken together, the average US tariff rate will rise to 15.2% if rates are implemented as announced, according to Bloomberg Economics. That's up from 13.3% earlier and significantly higher than the 2.3% in 2024 before Trump took office. Trump's country-based tariffs have been billed as the centerpiece of his plan to shrink trade deficits and pressure companies to shift manufacturing jobs and investment to the US. Trump previously delayed his so-called reciprocal tariffs, first announced in April, to allow time for negotiations as nations sought to obtain better trade terms. Some countries, including Switzerland and India, are still attempting to negotiate deals to lower their duties ahead of Thursday's deadline. Trump is expected to unveil separate tariffs on imports of pharmaceuticals, semiconductors, critical minerals and other key industrial products in the coming weeks, meaning ongoing uncertainty for companies and investors. And on Monday, he also threatened to impose 'substantially' higher levies on Indian exports to the US over New Delhi's purchases of Russian oil. While his tariffs are already bringing in billions in revenue for the US government, the longterm economic impacts remain unclear, with critics saying they will raise costs for US consumers and businesses and exacerbate inflation. (Updates with additional details, background throughout) AI Flight Pricing Can Push Travelers to the Limit of Their Ability to Pay Government Steps Up Campaign Against Business School Diversity What Happens to AI Startups When Their Founders Jump Ship for Big Tech How Podcast-Obsessed Tech Investors Made a New Media Industry Everyone Loves to Hate Wind Power. Scotland Found a Way to Make It Pay Off ©2025 Bloomberg L.P.
Yahoo
2 minutes ago
- Yahoo
Tariffs Starting to Slow Growth: Morgan Stanley's Zezas
Michael Zezas, Morgan Stanley's head of U.S. public policy research, says that over the next two to three months, we need to look carefully at inflation, labor data, as well as, product-by-product breakdowns to understand how the economy is absorbing tariff actions. He speaks to Romaine Bostick and Scarlet Fu on "The Close." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
4 minutes ago
- Wall Street Journal
Real Strains Inside the BLS Made It Vulnerable to Trump's Accusations
President Trump's decision to fire the head of the Bureau of Labor Statistics on Friday ignited a crisis at the U.S.'s top economic-stats agency. But it wasn't the start of the BLS's challenges. In the past few years, the BLS has faced tighter budgets and falling response rates to its surveys. In recent months, it has faced staff shortages brought on by a hiring freeze Trump declared in January.
